Irritable bowel syndrome (IBS) is a relapsing functional bowel disorder in which abdominal pain or discomfort is associated with defecation or a change in bowel habit. Bloating and distension are often associated. IBS is defined by symptom-based diagnostic criteria, in the absence of detectable organic causes. The symptoms are not specific for IBS. The diagnosis of IBS rarely alters over time, but always be prepared to reconsider the diagnosis if the clinical picture changes. IBS has a significant negative impact on quality of life and social functioning in many patients, but it is not associated with the development of serious disease or with excess mortality.
- IBS occurs in 10-20% of the population in the UK, but prevalence is thought to be higher than this as many people with the disorder do not seek medical advice.
- A systematic review of global prevalence showed significant geographical differences (between 1% and 45%).
- It is more common in women than in men, with a ratio of 1.67:1. Certain subtypes of IBS show different gender variability.
- Peak prevalence is between the ages of 20 and 30.
- There is no structural lesion, and no single explanation has been found to explain the condition. However, it seems to involve abnormal smooth muscle activity ± visceral hypersensitivity, and abnormal central processing of painful stimuli.
- IBS is associated with increased levels of psychiatric distress and poor coping strategies.
- There is evidence of abnormal bowel transit time in affected individuals, suggesting possible disturbed gastrointestinal motility.
- Balloon distension of the bowel in affected individuals leads to perception of pain at lower thresholds than those without it, suggesting some role of the central pain processing system.
- There can be aggregation of the condition in families.
- Subclasses of IBS have been identified as follows:
- Approximately one third of patients have IBS with constipation (IBS-C) = loose stools <25% and hard stools >25% of the time.
- Approximately one third of patients have IBS with diarrhoea (IBS-D) = loose stools >25% and hard stools <25% of the time.
- The remainder have IBS-mixed (IBS-M) = both hard and soft stools >25% of the time.
- Abdominal pain or discomfort.
- Change in bowel habit.
AND at least 2 of the following are present:
- Altered passage of stool (straining, urgency, incomplete evacuation).
- Abdominal bloating (women >men), distention tension or hardness.
- Symptoms aggravated by eating.
- Passage of mucus rectally.
Further notes on IBS features
- Most patients have abdominal pain and disordered bowel habit, continuous or intermittent. This may be predominantly diarrhoea, predominantly constipation, or alternating between the two. A 'morning rush' is common: patients feel the urgent need to defecate several times on getting up, during and after breakfast.
- Symptoms are chronic, with remissions interrupted by relapses precipitated by stress or changes in bowel flora produced by antibiotics.
- Symptoms may begin following an episode of gastroenteritis. Around one in ten people with IBS believe their symptoms began in this way. Diarrhoea tends to be the predominant symptom in this group.
- Upper gastrointestinal symptoms may include nausea, heartburn, dysphagia, and early satiety.
- Extra-intestinal symptoms such as headaches and migraine, asthma, backache, lethargy, dyspareunia, urinary frequency, and urgency are more commonly reported by patients with IBS. Psychological problems (anxiety and depression) are also more common, although some psychological morbidity appears to be associated with health care-seeking rather than with IBS per se.
On abdominal examination, signs may be few and nonspecific (eg, tender, palpable colon). A rectal ± pelvic examination may be appropriate.
- Colonic cancer.
- Inflammatory bowel disease (IBD): Crohn's disease, ulcerative colitis.
- Bile acid malabsorption.
- Coeliac disease.
- Gastroenteritis - eg, giardiasis.
- Diverticular disease.
- Gynaecological problems - eg, pelvic inflammatory disease, endometriosis, ovarian tumours.
- Anxiety ± depression, somatisation and panic disorders.
The diagnosis of IBS should be made positively on symptom-based criteria, NOT as a diagnosis of exclusion after ruling out organic disease by exhaustive investigation.
Carefully and sympathetically elicit a history and carry out an appropriately thorough physical examination. Ask about a family history of IBD or colon cancer, at age <50 - as this should lower the threshold for investigation/referral.
All patients meeting the symptomatic criteria for IBS should have the following investigations:
- Coeliac screen.
- CA 125 for women with symptoms which could be ovarian cancer.
- Faecal calprotectin for those with symptoms which could be IBD.
The following tests are NOT required to confirm IBS in those who meet the diagnostic criteria:
- Colonoscopy/sigmoidoscopy/barium enema.
- Faecal occult blood.
- Faecal ova and parasite tests.
- Hydrogen breath tests.
Refer patients in the event of diagnostic uncertainty, alarm symptoms, or severe resistant symptoms.
Referral to secondary care
|Refer patients with possible IBS for further investigation if any red flag symptoms are present:||Refer patients with possible IBS for further investigation if any red flag signs are present:|
An urgent two-week referral is occasionally appropriate - eg, weight loss, rectal bleeding, jaundice, abdominal mass, etc.
- Lower bowel investigations - colonoscopy, or sigmoidoscopy ± barium enema. A rectal biopsy may be appropriate (to diagnose IBD bowel disease).
- Gastroscopy may be appropriate if upper gastrointestinal symptoms predominate.
- Gynaecological referral may help rule out endometriosis and pelvic infection.
- Consider psychological referral if the main problems are inability to cope with symptoms.
Beware of unnecessary specialist referral and interventions - eg, hysterectomy and cholecystectomy. Referral may prolong anxiety as much as allay it.
Having confidently made the diagnosis, reassurance and explanation are vital, including frank explanation of the likely course of disease. Many patients may have a fear of cancer, but careful and often-repeated explanations of the nature of the disease reduce this.
Lifestyle and physical activity
- Provide information about the condition and self-help, covering lifestyle, physical activity, diet and symptom-targeted medication.
- Encourage patients to identify and make best use of leisure time, and create times in the day for relaxation.
- Assess physical activity levels and give advice on increasing activity if appropriate. There is evidence that increasing physical activity has a positive effect on symptoms.
General dietary advice
- Have regular meals - ie avoid long gaps between meals and don't rush them.
- Drink plenty of fluids (at least eight cups per day) but restrict tea/coffee to three cups or so per day.
- Reduce intake of alcohol and fizzy drinks.
- Consider limiting high-fibre foods (eg, wholemeal flour or bran), and resistant starches (often in processed or recooked foods, and fresh fruits - limit to three portions per day).
- For diarrhoea - avoid sorbitol.
- For wind - consider increasing oats and linseeds (one tablespoon/day).
Review fibre intake and adjust this in line with symptoms. Those with constipation as a predominant symptom may need to increase fibre intake, whereas those with diarrhoea may find the opposite helpful.
The results of the most recent meta-analyses of the benefits of soluble and insoluble fibre for IBS contradict each other. A Cochrane review found no benefit for either. Another review, however, found a benefit for soluble fibre, as ispaghula.
Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs)
Recently there has been interest in the role of FODMAPs in causing symptoms of IBS. Foods high in FODMAPs, such as apples, cherries, peaches, nectarines, artificial sweeteners, most lactose-containing foods, legumes, and many green vegetables (broccoli, Brussels sprouts, cabbage, and peas) may have fermentation and osmotic effects, increasing symptoms. Diets low in FODMAPs have therefore been advocated in helping symptoms. There is evidence to support this approach[16, 17, 18]. Up to 86% of people with IBS are said to report an improvement in symptoms, specifically bloating, abdominal pain, flatus and altered bowel habit, when using a low-FODMAP diet.
For those who find diet plays a significant role in their symptoms, referral to a dietician may be helpful for advice about exclusion diets, etc.
There is some evidence for probiotics being helpful in alleviating symptoms of IBS, but further studies are needed to make more specific recommendations about optimal regimes and products[20, 21]. NICE guidelines suggest if used, they should be taken for four weeks at the dose recommended by the manufacturer, while monitoring the effect.
- There is a high rate of placebo effect in IBS, even when the patient knows they are taking a placebo.
- Pharmacological options should target the individual symptoms, such as diarrhoea, abdominal spasm, bloating or constipation.
- Loperamide is the medication of choice for diarrhoea.
- Antispasmodics should be used as required for abdominal pain and spasms. A number of options are used. Otilonium, cimetropium, hyoscine, pinaverium, and dicycloverine have been demonstrated to be more effective than placebo in meta-analyses.
- Peppermint oil has also been shown to be effective, as an antispasmodic and for bloating, with very few adverse effects.
- Laxatives may be used as required for constipation. Linaclotide has recently been added to recommendations, to be considered when other laxatives have not worked and constipation has been present for 12 months. Avoid lactulose.
- Antidepressants have been shown to be of benefit, as in other chronic pain conditions. Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) have been shown convincingly to be effective, although studies have not been done in primary care[14, 23]. NICE guidelines advocate the use of an SSRI only if a low-dose TCA has not been effective. Treatment should be started at a low dose (for example, 10 mg amitriptyline) and increased if necessary to no more than 30 mg.
- Antibiotics may have a role in IBS by altering the bacterial composition of the gastrointestinal tract. Short-course therapy with rifaximin or neomycin has been shown to be of benefit, but further studies are needed[21, 24, 25].
- Emerging therapies under evaluation include:
Dr Hayley Willacy draws your attention to the latest decision by NICE to approve eluxadoline. This treatment will be available routinely under the NHS for the treatment of patients with irritable bowel syndrome and diarrhoea (IBS-D) from within secondary care. Eluxadoline acts by binding to specific receptors in the digestive system and slowing down the passage of food through the gut, relieving stomach cramps and the urgent need to open the bowels. Treatment should not be continued beyond four weeks, if there is no clinical response. It may be given along with existing therapies for IBS-D, including antispasmodics or hypnotherapy.
- Psychological therapy may be considered for individuals not responding to other treatment options after a year. This may include cognitive behavioural therapy (CBT), mindfulness training, hypnotherapy or psychotherapy. There is limited evidence for efficacy of these options[23, 29]. The best evidence available currently is for hypnotherapy, but it is only effective when used in specialised centres.
- Acupuncture has been used although a Cochrane review found no benefit. NICE guidance advises against the use of acupuncture or reflexology for IBS.
- Benefits of herbal therapies remain unclear. There is limited evidence for a commercially available preparation known as STW 5, or Iberogast®. Further trials are needed on herbal remedies before advice can be given on their use. Aloe vera is not recommended.
- Symptoms fluctuate over many years. More than 50% will continue to have symptoms after seven years.
- People with a long history of IBS are less likely to improve.
- Ongoing stress may hinder recovery.
- IBS is not associated with the long-term development of any serious disease, although individuals with IBS are more likely to undergo certain surgical operations (eg, hysterectomy or cholecystectomy) than controls. Those with IBS have been shown to have an increased risk of cholecystectomy which is not due to an increased risk of gallstones. It appears to be related to abdominal pain, increased awareness of gallstones and inappropriate surgical indications.
- The postinfective subgroup appears to have a better prognosis, with symptoms resolving in many within 5-6 years[36, 37].
Further reading and references
Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care; NICE Clinical Guideline (February 2008, updated April 2017)
Irritable bowel syndrome in adults; NICE Quality Standard, February 2016
Irritable bowel syndrome: a global perspective; World Gastroenterology Organisation Global Guideline, April 2009
Guidelines on the Irritable Bowel Syndrome: Mechanisms and Practical Management; British Society of Gastroenterology (May 2007)
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel; NICE Diagnostics Guidance (Oct 2013)
Lovell RM, Ford AC; Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul10(7):712-721.e4. doi: 10.1016/j.cgh.2012.02.029. Epub 2012 Mar 15.
Lovell RM, Ford AC; Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012 Jul107(7):991-1000. doi: 10.1038/ajg.2012.131. Epub 2012 May 22.
Irritable bowel syndrome in adults; NICE Clinical Guideline (February 2008)
Ford AC, Talley NJ; Irritable bowel syndrome. BMJ. 2012 Sep 4345:e5836. doi: 10.1136/bmj.e5836.
Spiller R; Clinical update: irritable bowel syndrome. Lancet. 2007 May 12369(9573):1586-8.
Dalrymple J, Bullock I; Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. BMJ. 2008 Mar 8336(7643):556-8.
Spiller R, Garsed K; Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May136(6):1979-88. doi: 10.1053/j.gastro.2009.02.074. Epub 2009 May 7.
Spiller R, Aziz Q, Creed F, et al; Guidelines for the management of Irritable Bowel Syndrome. Gut. 2007 May 8.
Ovarian cancer - the recognition and initial management of ovarian cancer; NICE Clinical Guideline (April 2011)
Johannesson E, Simren M, Strid H, et al; Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011 May106(5):915-22. doi: 10.1038/ajg.2010.480. Epub 2011 Jan 4.
Ruepert L, Quartero AO, de Wit NJ, et al; Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011 Aug 10(8):CD003460.
Ford AC, Talley NJ, Spiegel BM, et al; Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008 Nov 13337:a2313. doi: 10.1136/bmj.a2313.
Ong DK, Mitchell SB, Barrett JS, et al; Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010 Aug25(8):1366-73. doi: 10.1111/j.1440-1746.2010.06370.x.
Gibson PR, Shepherd SJ; Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010 Feb25(2):252-8. doi: 10.1111/j.1440-1746.2009.06149.x.
Shepherd SJ, Lomer MC, Gibson PR; Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013 May108(5):707-17. doi: 10.1038/ajg.2013.96. Epub 2013 Apr 16.
Barrett JS; Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013 Jun28(3):300-6. doi: 10.1177/0884533613485790. Epub 2013 Apr 24.
Moayyedi P, Ford AC, Talley NJ, et al; The efficacy of probiotics in the treatment of irritable bowel syndrome: a Gut. 2010 Mar59(3):325-32. Epub 2008 Dec 17.
Cash BD; Emerging Role of Probiotics and Antimicrobials in the Management of Irritable Bowel Syndrome. Curr Med Res Opin. 2014 Mar 26.
Kaptchuk TJ, Friedlander E, Kelley JM, et al; Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010 Dec 225(12):e15591. doi: 10.1371/journal.pone.0015591.
Ford AC, Talley NJ, Schoenfeld PS, et al; Efficacy of antidepressants and psychological therapies in irritable bowel Gut. 2009 Mar58(3):367-78. Epub 2008 Nov 10.
Pimentel M, Lembo A, Chey WD, et al; Rifaximin therapy for patients with irritable bowel syndrome without N Engl J Med. 2011 Jan 6364(1):22-32.
Menees SB, Maneerattannaporn M, Kim HM, et al; The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan107(1):28-35
Evans BW, Clark WK, Moore DJ, et al; Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev. 2007 Oct 17(4):CD003960.
Fashner J, Gitu AC; Common gastrointestinal symptoms: irritable bowel syndrome. FP Essent. 2013 Oct413:16-23.
Irritable bowel syndrome (diarrhoea) - eluxadoline [ID870]; NICE Technology appraisal (in development) expected publication August 30th 2017
Zijdenbos IL, de Wit NJ, van der Heijden GJ, et al; Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009 Jan 21(1):CD006442. doi: 10.1002/14651858.CD006442.pub2.
Lindfors P, Unge P, Arvidsson P, et al; Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol. 2012 Feb107(2):276-85. doi: 10.1038/ajg.2011.340. Epub 2011 Oct 4.
Manheimer E, Cheng K, Wieland LS, et al; Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012 May 165:CD005111. doi: 10.1002/14651858.CD005111.pub3.
Madisch A, Holtmann G, Plein K, et al; Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004 Feb 119(3):271-9.
Liu JP, Yang M, Liu YX, et al; Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006 Jan 25(1):CD004116.
Irritable bowel syndrome; NICE CKS, February 2013 (UK access only)
Corazziari E, Attili AF, Angeletti C, et al; Gallstones, cholecystectomy and irritable bowel syndrome (IBS) MICOL population-based study. Dig Liver Dis. 2008 Dec40(12):944-50. doi: 10.1016/j.dld.2008.02.013. Epub 2008 Apr 10.
Jung IS, Kim HS, Park H, et al; The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study. J Clin Gastroenterol. 2009 Jul43(6):534-40. doi: 10.1097/MCG.0b013e31818c87d7.
Rhodes DY, Wallace M; Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep. 2006 Aug8(4):327-32.
Can anyone help? I have my doctor ringing Monday, tomorrow. I need to know what this I but the camera test went wrong. Help how do i explain to my doctor what went wrong? Also can i ask how can you...sam18386
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. Patient Platform Limited has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.